Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Beneficial cilostazol therapeutic effects in mdx dystrophic skeletal muscle

Full text
Hermes, Tulio de Almeida [1] ; Macedo, Aline Barbosa [1] ; Fogaca, Aline Reis [1] ; Rapucci Moraes, Luis Henrique [1] ; de Faria, Felipe Meira [1] ; Kido, Larissa Akemi [1] ; Alves Cagnon, Valeria Helena [1] ; Minatel, Elaine [1]
Total Authors: 8
[1] State Univ Campinas UNICAMP, Inst Biol, Dept Struct & Funct Biol, BR-13083970 Campinas, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Clinical and Experimental Pharmacology and Physiology; v. 43, n. 2, p. 259-267, FEB 2016.
Web of Science Citations: 5

This study evaluated the possible protective effects of cilostazol against myonecrosis in dystrophic diaphragm muscle invivo, focusing on oxidative stress, the inflammatory response and angiogenesis. Young mdx mice, the experimental animal for Duchenne muscular dystrophy, received cilostazol for 14days. A second group of mdx mice and a control group of C57BL/10 mice received a saline solution. In the mdx mice, cilostazol treatment was associated with reduced loss of muscle strength (-34.4%), decreased myonecrosis, reduced creatine kinase levels (-63.3%) and muscle fibres stained for immunoglobulin G in dystrophic diaphragm muscle (-81.1%), and a reduced inflammatory response, with a decreased inflammatory area (-22%), macrophage infiltration (-44.9%) and nuclear factor-B (-24%) and tumour necrosis factor- (-48%) content in dystrophic diaphragm muscle. Furthermore, cilostazol decreased oxidative stress and attenuated reactive oxygen species production (-74%) and lipid peroxidation (-17%) in dystrophic diaphragm muscle, and promoted the up-regulation of angiogenesis, increasing the number of microvessels (15%). In conclusion, the present results show that cilostazol has beneficial effects in dystrophic muscle. More research into the potential of cilostazol as a novel therapeutic agent for the treatment of dystrophinopathies is required. (AU)

FAPESP's process: 11/02474-4 - Treatment in vivo and in vitro with calcium blocker and antioxidant in mdx mice
Grantee:Elaine Minatel
Support Opportunities: Regular Research Grants
FAPESP's process: 13/17299-9 - Effect of the combination of anti-inflammatory and antioxidant on dystrophic muscle cells
Grantee:Aline Reis Fogaça
Support Opportunities: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 13/01294-8 - The controversial relationship between inflammation and prostatic lesions: treatment with Celecoxib and Goniothalamin in senile and Tramp mice
Grantee:Larissa Akemi Kido de Barros
Support Opportunities: Scholarships in Brazil - Doctorate